Pfizer, Genmab Get Speedy FDA Review of Tivdak Full Approval
By Colin Kellaher
Pfizer and Genmab on Tuesday said the U.S. Food and Drug Administration granted priority review to their request to convert the accelerated approval of Tivdak for certain patients with cervical cancer to full approval.
The companies said the FDA has set a target action date of May 9 for the application, which is based on positive results from a global Phase 3 study that showed overall survival benefit of Tivdak over chemotherapy in patients with recurrent or metastatic cervical cancer with disease progression on or after first-line therapy.
The FDA granted accelerated approval to Tivdak in September 2021.
Copenhagen biotechnology company Genmab and Seagen, which New York-based Pfizer acquired last year in a $43 billion deal, are co-developing Tivdak by Genmab and Seagen, under an agreement in which the companies share costs and profits for the product on a 50-50 basis.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
January 09, 2024 07:30 ET (12:30 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
5 Stocks to Buy While They’re Trading at Big Discounts
-
Markets Brief: Tech Stocks Lead Ahead of Nvidia Earnings
-
How Anti-Obesity Drugs Are Innovating the Healthcare Market
-
What’s Happening In the Markets This Week
-
Why Immigration Has Boosted Job Gains and the Economy
-
What to Invest in During High Inflation
-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
Should You Buy and Hold an Artificial Intelligence Portfolio?
-
3 Cheap and Dependable Dividend-Growth Stocks to Buy
-
The Best Bank Stocks to Buy
-
After Earnings, Is Roblox Stock a Buy, Sell, or Fairly Valued?
-
After Earnings, Is Lyft Stock a Buy, a Sell, or Fairly Valued?
-
8 Stock Picks in the Apparel Industry
-
Baidu Earnings: Advertising Weakness Offset by Continued Growth In Cloud Business
-
Going Into Earnings, Is Target Stock a Buy, a Sell, or Fairly Valued?